First, we observed an increase in the CD8+ T cell population in spleens of mice treated with PeptiCRAd (Figure 4C) compared to other groups; to dissect the functional profile of those CD8+ T cells, an INF-γ ELISPOT assay was performed on the spleen of the treated mice; upon TRP2 stimulus the production of IFN-γ increased significantly in PeptiCRAd treated mice, highlighting systemic generation of specific anti-tumor T cells following PeptiCRAd treatment (Figure 4D). Here, CD8A is linked to neoplasm.